May 25, 2022— Federal appeals courts are considering legal challenges to the government’s authority to require drug companies to restore 340B drug pricing program discounts on drugs dispensed at community and specialty pharmacies. In a series of legal briefs filed with two of the courts, five national hospital associations and 25 state attorneys general urged the courts to … [Read more...]
340B Community Pharmacy Legal Battle Moves to Next Stage
April 18, 2022— A nearly two-year dispute between hospitals participating in the 340B drug discount program and a group of drug companies pulling back from their 340B commitments has fully entered a new phase of legal wrangling. Over the coming months, three federal appeals courts will review lower court decisions that came to differing conclusions on what federal law says … [Read more...]
More Court Battles Ahead for 340B in 2022
Jan. 12, 2022– The dispute between safety-net hospitals and a growing group of drug companies over community-based pharmacies in the 340B drug pricing program is heading into a new phase of legal wrangling that ensures this fight will remain a dominant issue in the 340B world for months to come. As 2021 ended, two industry giants – Amgen and AbbVie – joined the group of … [Read more...]
Recapping a Momentous Year for 340B
Dec. 31, 2021– Today is the final day of what might be one of the most eventful years in the history of the 340B drug pricing program. Key developments in the 340B world stood out even amid all the news about a global pandemic, a change in leadership in Washington, and an uneasy economic climate. As we wrap up 2021 and look forward to a new year, we are reflecting on some of … [Read more...]